Abstract
: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (a...
Funding Information
  • National Cancer Institute

This publication has 105 references indexed in Scilit: